Gabriel S. Morris net worth and biography

Gabriel Morris Biography and Net Worth

CFO of Immix Biopharma

Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding.

Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a growth equity financing round. Prior, Mr. Morris led cross-border mergers & acquisitions transactions at Goldman Sachs and other global investment banks for more than a decade, where he participated in greater than $50 billion in completed transactions. Mr. Morris received his B.A. from the Columbia University in the City of New York.

What is Gabriel S. Morris' net worth?: The estimated net worth of Gabriel S. Morris is at least $2.66 million as of December 10th, 2025. Morris owns 291,429 shares of Immix Biopharma stock worth more than $2,659,290 as of March 26th. This net worth evaluation does not reflect any other investments that Morris may own. Learn More about Gabriel S. Morris' net worth.
How do I contact Gabriel S. Morris?: The corporate mailing address for Morris and other Immix Biopharma executives is , , . Immix Biopharma can also be reached via phone at 310-651-8041. Learn More on Gabriel S. Morris' contact information.
Has Gabriel S. Morris been buying or selling shares of Immix Biopharma?: Gabriel S. Morris has not been actively trading shares of Immix Biopharma within the last three months. Most recently, on Wednesday, December 10th, Gabriel S. Morris bought 770 shares of Immix Biopharma stock. The stock was acquired at an average cost of $6.58 per share, with a total value of $5,066.60. Following the completion of the transaction, the chief financial officer now directly owns 291,429 shares of the company's stock, valued at $1,917,602.82. Learn More on Gabriel S. Morris' trading history.
Who are Immix Biopharma's active insiders?: Immix Biopharma's insider roster includes Jason Hsu (Director), and Gabriel Morris (CFO). Learn More on Immix Biopharma's active insiders.
Are insiders buying or selling shares of Immix Biopharma?: In the last twelve months, Immix Biopharma insiders bought shares 6 times. They purchased a total of 11,019 shares worth more than $30,275.04. The most recent insider tranaction occured on December, 10th when CEO Ilya M Rachman bought 746 shares worth more than $4,975.82. Insiders at Immix Biopharma own 55.4% of the company. Learn More about insider trades at Immix Biopharma.
Information on this page was last updated on 12/10/2025.

Gabriel S. Morris Insider Trading History at Immix Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2025	Buy	770	$6.58	$5,066.60	291,429
9/16/2025	Buy	2,600	$1.97	$5,122.00	290,659
6/18/2025	Buy	2,225	$2.28	$5,073.00	288,059
6/7/2024	Buy	2,500	$2.12	$5,300.00	285,834
6/4/2024	Buy	3,300	$1.81	$5,973.00	283,334
5/14/2024	Buy	4,500	$2.23	$10,035.00	85,816

Gabriel S. Morris Buying and Selling Activity at Immix Biopharma

Immix Biopharma Company Overview

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Today's Range

Now: $9.14

$8.12

$9.52

50 Day Range

MA: $7.62

$4.60

$11.12

2 Week Range

Now: $9.14

$1.34

$11.61

Volume

333,693 shs

Average Volume

878,537 shs

Market Capitalization

$484.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25